86 related articles for article (PubMed ID: 13945399)
1. [Preliminary report on a new orally active gestagen (SH 714)].
FIXSON U
Geburtshilfe Frauenheilkd; 1963 Apr; 23():371-8. PubMed ID: 13945399
[No Abstract] [Full Text] [Related]
2. [A NEW VERY EFFICACIOUS GESTAGEN, STG 155 (GESTATORTIN E, MERCK)].
VOEGE A; SCHOEPF E
Zentralbl Gynakol; 1964 Feb; 86():197-202. PubMed ID: 14161939
[No Abstract] [Full Text] [Related]
3. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins.
Amiri M; Ramezani Tehrani F; Nahidi F; Kabir A; Azizi F; Carmina E
Metabolism; 2017 Aug; 73():22-35. PubMed ID: 28732568
[TBL] [Abstract][Full Text] [Related]
5. [THERAPEUTIC OVARIAN INHIBITION BY SYNTHETIC PROGESTATIONAL HORMONES].
MAUVAIS-JARVIS P; DECOURT J
Sem Hop; 1964 Nov; 40():2659-69. PubMed ID: 14233565
[No Abstract] [Full Text] [Related]
6. The effect of progesterone and progestational antiandrogen cyproterone acetate on the ovaries and the adrenal glands of neonatally androgenised rats.
Shanbhag AB; Nevagi SA; Nadkarni VB
Exp Clin Endocrinol; 1987 Mar; 89(1):7-15. PubMed ID: 2954836
[TBL] [Abstract][Full Text] [Related]
7. [THE STUDY OF STEROID BIOSYNTHESIS IN THE HUMAN OVARY. I. PRELIMINARY NOTE: EXPERIENCES "IN VITRO" WITH STEROIDS LABELED WITH C14].
FORLEO R; INGRASSIA F
Riv Ostet Ginecol; 1963 Nov; 18():597-614. PubMed ID: 14103778
[No Abstract] [Full Text] [Related]
8. [CLINICAL EXPERIENCE WITH THE NEW PERORAL GESTAGEN, 16-METHYLENE-6-DEHYDRO-17-ALPHA-ACETOXYPROGESTERONE (MDAP)].
HONTELA S
Zentralbl Gynakol; 1964 Sep; 86():1327-32. PubMed ID: 14324038
[No Abstract] [Full Text] [Related]
9. [6alpha-Methyl-17alpha-hydroxyprogesterone acetate (MAP) in high doses and the hypophysis. Experimental contribution].
VERNA F; CASTIGLIONE C
Minerva Ginecol; 1962 Sep; 14():861-8. PubMed ID: 13996820
[No Abstract] [Full Text] [Related]
10. [CONTRIBUTION TO THE CLINICAL STUDY OF A NEW ORALLY ACTIVE PROGESTATIONAL COMPOUND: CHLORMADINONE].
SALLESADE A; PEANO M
Rev Ginecol Obstet (Sao Paulo); 1963 Aug; 113():39-48. PubMed ID: 14167946
[No Abstract] [Full Text] [Related]
11. Effects of cyproterone on the steroid biosynthesis in the human ovary in vitro.
Schürenkämper P; Lisse K
Endokrinologie; 1982 Nov; 80(3):281-6. PubMed ID: 7166160
[TBL] [Abstract][Full Text] [Related]
12. [SYNTHETIC PROGESTATIONAL HORMONES AND INHIBITION OF OVULATION].
PUJOLAMAT P
Med Clin (Barc); 1963 Nov; 41():396-405. PubMed ID: 14112383
[No Abstract] [Full Text] [Related]
13. [INDUCTION OF OVULATION BY GONADOTROPINS, INHIBITION OF OVULATION BY GESTAGENS].
HOHLWEG W; REIFFENSTUHL G; SCHMOER J
Bibl Gynaecol; 1965; 32():14-21. PubMed ID: 14238627
[No Abstract] [Full Text] [Related]
14. Treatment of endometriosis with cyproterone acetate. Preliminary report.
Morán C; Alcivia JC; García-Hernández E; Castro J
Arch Med Res; 1996; 27(4):535-8. PubMed ID: 8987191
[TBL] [Abstract][Full Text] [Related]
15. EFFECTS OF THE OVARY OF PROLONGED ADMINISTRATION OF LYNESTRENOL: A HISTOLOGICAL STUDY.
LAUWERYNS J; FERIN J
Int J Fertil; 1964; 9():35-9. PubMed ID: 14106266
[No Abstract] [Full Text] [Related]
16. [CLINICAL TRIAL OF 19-NORETHYNYLTESTOSTERONE ENANTHATE].
ASHIDAKA Y; TAKEMURA T; SUZUKI S; TAKAYAMA K; KAWABATA K; MINAMI Y; KOIZUMI R; TATETSU M
Sanfujinka Chiryo; 1964 Jan; 8():107-15. PubMed ID: 14115191
[No Abstract] [Full Text] [Related]
17. STUDIES ON MENSTRUAL DISORDERS. V. EVALUATION OF VARIOUS THERAPIES FOR MENSTRUAL DISORDERS.
MATSUMOTO S; IGARASHI M; SATO S; SATO T; OZAWA M; HOSAKA H; TOHMA K; ITO T; KAMIOKA J; MICHISHITA T; TAMURA K; OKAMOTO S; TSUKAGOSHI M; KUBO H; SAKAKIBARA A
J Jpn Obstet Gynecol Soc; 1963 Jul; 10():161-80. PubMed ID: 14102888
[No Abstract] [Full Text] [Related]
18. [Rationale for prescribing oral contraceptives].
Teichmann AT
Wien Med Wochenschr; 1998; 148(7):171-4. PubMed ID: 9700865
[TBL] [Abstract][Full Text] [Related]
19. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
Bitzer J; Amy JJ; Beerthuizen R; Birkhäuser M; Bombas T; Creinin M; Darney PD; Vicente LF; Gemzell-Danielsson K; Imthurn B; Jensen JT; Kaunitz AM; Kubba A; Lech MM; Mansour D; Merki G; Rabe T; Sedlecki K; Serfaty D; Seydoux J; Shulman LP; Sitruk-Ware R; Skouby SO; Szarewski A; Trussell J; Westhoff C
J Fam Plann Reprod Health Care; 2013 Jul; 39(3):156-9. PubMed ID: 23585363
[No Abstract] [Full Text] [Related]
20. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
Bitzer J; Amy JJ; Beerthuizen R; Birkhäuser M; Bombas T; Creinin M; Darney PD; Vicente LF; Gemzell-Danielsson K; Imthurn B; Jensen JT; Kaunitz AM; Kubba A; Lech MM; Mansour D; Merki G; Rabe T; Sedlecki K; Serfaty D; Seydoux J; Shulman LP; Sitruk-Ware R; Skouby SO; Szarewski A; Trussell J; Westhoff C
Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):143-7. PubMed ID: 23578274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
